Findings from PENN2 Study
Home » Guardant360® » Findings from PENN2 Study

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer1

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer1

“These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solid tissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.” 2

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

*JAMA Oncol. 2019;5(2):148-149.
doi:10.1001/jamaoncol.2018.4304

concordanse

for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF

“These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solid tissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.” 2

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

*JAMA Oncol. 2019;5(2):148-149.
doi:10.1001/jamaoncol.2018.4304

concordanse

for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360® can increase the likelihood of finding targetable mutations.

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360® can increase the likelihood of finding targetable mutations.

Key findings

Key findings

were unable to get genomic results
from tissue biopsy

had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.

had an objective tumor response or stable disease based on RECIST

44_patients_agree_tissue_testing

were unable to get genomic results
from tissue biopsy

1.7x_as_many_patients

had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.

853.7_percentage

had an objective tumor response or stable disease based on RECIST

You may also be interested in…

Reference:

1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180.

2. Bishal G, Howard JW. Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither? JAMA Oncol 2019 Feb 1;5(2):148-149.

MKTAMEA112020_015

Open chat
Message us